Related names in cited records: Zepbound, Mounjaro↗
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.↗↗
Citation markers ↗ open the public records supporting the adjacent statements.
Correction · September 15, 2026
We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope. 1
U.S. label record. The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.↗↗
What the reviewed sources report
The reviewed obesity trial reported greater weight reduction with tirzepatide than placebo, and the reviewed type 2 diabetes trial reported lower glycated hemoglobin and body weight than placebo. These trials do not answer every population, long-term outcome, or post-discontinuation question.↗↗
What remains unresolved?
What are the durability, post-discontinuation outcomes, and uncommon harms across broader populations and longer follow-up?↗↗
The cited Zepbound label covers long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. Both indications are described alongside diet and physical activity. This is a product-specific account, separate from Mounjaro labeling. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rats, with uncertain human relevance. Contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2 and serious hypersensitivity. Warnings address severe gastrointestinal reactions, kidney injury from volume depletion, gallbladder disease, pancreatitis, hypoglycemia, diabetic retinopathy complications and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 4fe25d4173ba662adc2b4ac0653c09643bc7a9e883557286abe2c5d36f19d87e. Extracted XML SHA-256: 7c40611952c42e85d4688669dae2a5529cd563e0e857fdb23e411a8f7d8b0f14.
On January 13, 2026, FDA requested removal of the suicidal-behavior and ideation warning from Zepbound labeling after its review found no increased risk. This records the agency’s request, not a claim that every label version has changed. FDA PDF pp. 1 ↗
More findings and the sources behind them
Selected FDA safety communications, read alongside the separately preserved product-label account and human evidence review.
What supported that finding
FDA combined 91 placebo-controlled trials involving 107,910 participants and examined a separate Sentinel claims cohort. These are class-wide analyses, not a dedicated trial of this peptide or a finding about every possible adverse effect. FDA PDF pp. 2, 3 ↗
Reports about compounded products need context
FDA reports adverse events associated with compounded tirzepatide, while noting underreporting and uncertain causality. Raw report totals do not establish an incidence rate or a fair comparison with approved products. FDA source ↗
What remains to be checked
Reconcile each current product and formulation label with subsequent safety and indication changes.
Appraise remaining eligible trial reports and follow-up studies; this update does not complete the literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
EMA’s July 2022 assessment covers SURPASS-1 through SURPASS-5 in type 2 diabetes. Placebo comparisons were blinded, while several active-comparator trials were open-label and used different background therapies. EMA PDF pp. 203 ↗
More findings, study links and document coverage
An effect estimate depends on what happened after discontinuation
The review distinguishes an analysis including treatment changes and nonadherence from an efficacy analysis assuming intended treatment without rescue. These address different questions and should not be merged into one headline estimate. EMA PDF pp. 204 ↗
Comparisons apply to the regimens actually studied
The assessment found greater glycemic and weight improvements than its studied comparators, including the then-studied semaglutide regimen. This does not establish superiority over every formulation, regimen, population or later trial. EMA PDF pp. 203, 204 ↗
Important populations were sparsely represented
EMA noted limited clinical evidence in severe kidney or liver impairment, alongside gastrointestinal adverse effects and treatment discontinuations. This original diabetes assessment is distinct from later weight-management and other indication reviews. EMA PDF pp. 205, 211 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
European medicine records · 1 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: tirzepatide. EMA record ↗
Marketing authorisation: 2022-09-15. EMA metadata last updated 2026-08-28. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
2536 retrieved · 2 included · 0 excluded · 2534 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Tirzepatide"[Title/Abstract] OR "LY3298176"[Title/Abstract] OR "Zepbound"[Title/Abstract] OR "Mounjaro"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Linked correction notices require comparison with the selected reports: PMID34274062 for PMID34186022. Their presence does not establish what changed.
Showing 25 of 2536 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 35658024 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04184622.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 34186022 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03954834.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed links an erratum: Department of Error. ↗. Impact on the selected study summary remains unresolved.
Notice XML SHA-256 77b4137f3d2d133936904bcae84dd9ceb73746fc92a75dcbfd9962b1a50ac157.
PubMed 42738922 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735883 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735880 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42735799 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42733229 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42733128 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732962 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732434 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730175 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730051 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729808 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729636 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42728528 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727867 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727208 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42723821 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42722006 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42721915 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA217806 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TIRZEPATIDE.
FDA NDA215866 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TIRZEPATIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005620 — include: EMA feed product Mounjaro; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
27 retrieved · 14 included · 0 excluded · 13 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 27 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 56782 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Public assessment report
EMA 62228 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-PSUSA-00011019-202211 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 62456 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-005620-II-0007 : EPAR - Assessment report - Variation
EMA 56780 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - All authorised presentations
EMA 65380 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-PSUSA-00011019-202311 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 66627 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-005620-II-0027 : EPAR - Assessment report - Variation
EMA 67371 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-PSUSA-00011019-202405 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 57804 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 56778 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Medicine Overview
EMA 75020 — include: Document linked by EMA product number; content unappraised. Mounjaro-H-C-005620-II-0038 : EPAR - Assessment report - Variation
EMA 75019 — include: Document linked by EMA product number; content unappraised. Mounjaro-VR-0000281937 : EPAR - Assessment report - Variation
EMA 56779 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Product Information
EMA 71029 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Product information - tracked changes
EMA 67859 — include: Document linked by EMA product number; content unappraised. Mounjaro : EPAR - Procedural steps taken and scientific information after authorisation
EMA 55640 — not screened: Title-name match awaiting identity and document review. CHMP summary of positive opinion for Mounjaro
EMA 60836 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Mounjaro (II-07)
EMA 66099 — not screened: Title-name match awaiting identity and document review. Questions and answers on the outcome of assessment on use of Mounjaro in treatment of obstructive sleep apnoea
EMA 64106 — not screened: Title-name match awaiting identity and document review. P/0285/2023 : EMA decision of 24 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M01)
EMA 62016 — not screened: Title-name match awaiting identity and document review. P/0033/2023 : EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tirzepatide (Mounjaro) (EMEA-002360-PIP02-22)
EMA 58712 — not screened: Title-name match awaiting identity and document review. P/0174/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (EMEA- 002360-PIP01-18-M02)
EMA 58171 — not screened: Title-name match awaiting identity and document review. P/0540/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (EMEA-002360-PIP01-18-M01)
EMA 47070 — not screened: Title-name match awaiting identity and document review. P/0311/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tirzepatide (EMEA-002360-PIP01-18)
EMA 66804 — not screened: Title-name match awaiting identity and document review. P/0478/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M02)
EMA 71723 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Mounjaro (EMAVR0000281937)
EMA 72384 — not screened: Title-name match awaiting identity and document review. Questions and answers on the outcome of assessment on use of Mounjaro in treatment of heart failure with preserved ejection fraction in adults with obesity
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
303 retrieved · 0 included · 0 excluded · 303 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 303 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT06606821 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07697391 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06994338 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07194317 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07382180 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07555730 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07720466 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06914154 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05812183 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06467604 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07299084 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07423247 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06584916 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07756359 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06732245 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06790225 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06515418 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04050670 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06373146 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06779929 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05708859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04004988 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03311724 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05990374 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05564039 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Tirzepatide?
A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.12
Bottom line from this bounded source set
The reviewed obesity trial reported greater weight reduction with tirzepatide than placebo, and the reviewed type 2 diabetes trial reported lower glycated hemoglobin and body weight than placebo. These trials do not answer every population, long-term outcome, or post-discontinuation question.12
Reviewed study record
SURMOUNT-1 obesity trial
Design
A double-blind, randomized, placebo-controlled Phase 3 trial assessed body-weight change over 72 weeks.1
Population
The trial randomized 2,539 adults with obesity, or overweight plus at least one weight-related complication, and excluded people with diabetes.1
Outcomes reported
Reported mean body-weight change at week 72 ranged from -15.0% to -20.9% across tirzepatide groups and was -3.1% with placebo. Gastrointestinal events were the most common adverse events, and discontinuation for adverse events was more frequent in the tirzepatide groups.1
Limitations
The sponsor-funded trial used a dose-escalation period, excluded diabetes, and does not by itself establish outcomes after treatment stops or uncommon harms over longer periods.1
Reviewed study record
SURPASS-1 type 2 diabetes trial
Design
A double-blind, randomized, placebo-controlled Phase 3 trial assessed glycated hemoglobin, body weight, safety, and tolerability over 40 weeks.2
Population
The trial randomized 478 adults with type 2 diabetes inadequately controlled by diet and exercise who had not previously used injectable diabetes therapy.2
Outcomes reported
Reported mean glycated-hemoglobin change ranged from -1.87 to -2.07 percentage points across tirzepatide groups and was +0.04 with placebo. Reported body-weight reduction ranged from 7.0 to 9.5 kilograms, and gastrointestinal events were the most frequent adverse events.2
Limitations
The sponsor-funded trial was limited to 40 weeks and a treatment-naive type 2 diabetes population. Crossref also registers a publisher erratum for this publication; metadata alone does not describe the corrected wording.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2206038. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Publication update registered by CrossrefErratum ↗ · publisher metadata · July 17, 2021. Crossref metadata identifies the notice but does not by itself explain what wording changed.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Tirzepatide?
U.S. label record. The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through September 15, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationRecruiting 10Not yet recruiting 5Completed 2Active, not recruiting 1Enrolling by invitation 1
A phase value is unavailable here for 48 selected records; this is not counted as “no phase.”
A status value is unavailable here for 48 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
24 of 66 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 15Letter 6Editorial 2Published Erratum 2Review 2Case Reports 1Clinical Trial, Phase III 1Comment 1Meta-Analysis 1Multicenter Study 1Observational Study 1Preprint 1Randomized Controlled Trial 1Systematic Review 1
Bibliography fields unavailable here for 42 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
2
FDA Federal Register documents
8
DailyMed SPL versions
22
Canonical profile
Published
Profile structured data
Published
Linked dated records
169
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PubMed lists PMID 42695200 in Oral diseases as Letter, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.↗